Amicus Therapeutics (FOLD)

1.Callidus Biopharma, Inc. • 2.Celenex, Inc. • 3.Scioderm, Inc. • 4.MiaMed, Inc. • 5.Amicus Therapeutics International Holding Limited • 6.Amicus Therapeutics UK Limited • 7.Amicus Therapeutics UK Operations Limited • 8.Amicus Therapeutics SAS • 9.Amicus Therapeutics B.V. • 10.Amicus Therapeutics GmbH ...

IRS number

200422823

FOLD stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

S-8

Registration of securities for employees

5 Jun 25

8-K

Submission of Matters to a Vote of Security Holders

1 May 25

Amicus Therapeutics Announces First Quarter 2025Financial Results and Corporate Updates

1 May 25

8-K

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

1 May 25

ARS

2024 FY

Annual report to shareholders

24 Apr 25

DEFA14A

Additional proxy soliciting materials

24 Apr 25

Financial Statements and Exhibits

21 Feb 25

424B5

Prospectus supplement for primary offering

21 Feb 25

Transcripts

View all

FOLD

Earnings call transcript

2024 Q3

6 Nov 24

FOLD

Earnings call transcript

2024 Q2

8 Aug 24

FOLD

Earnings call transcript

2024 Q1

9 May 24

FOLD

Earnings call transcript

2023 Q4

28 Feb 24

FOLD

Earnings call transcript

2023 Q3

8 Nov 23

FOLD

Earnings call transcript

2023 Q2

8 Aug 23

FOLD

Earnings call transcript

2023 Q1

10 May 23

FOLD

Earnings call transcript

2022 Q4

1 Mar 23

FOLD

Earnings call transcript

2022 Q3

7 Nov 22

FOLD

Earnings call transcript

2022 Q2

5 Aug 22

Latest ownership filings

View all

PERCEPTIVE ADVISORS LLC

15 May 25

SC 13G/A

Avoro Capital Advisors LLC

15 May 25

Financial summary

Financial statements Chart FOLD financial data

Quarter (USD)	Mar 25	Dec 24	Sep 24	Jun 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	184.73 mm	184.73 mm	184.73 mm	184.73 mm	184.73 mm	184.73 mm
Cash burn (monthly)	10.66 mm	2.34 mm	6.02 mm	(no burn)	(no burn)	(no burn)
Cash used (since last report)	37.49 mm	8.22 mm	21.15 mm	n/a	n/a	n/a
Cash remaining	147.25 mm	176.51 mm	163.58 mm	n/a	n/a	n/a
Runway (months of cash)	13.8	75.5	27.2	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

FOLD institutional ownership history Ownership history

99.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	284	286	-0.7%
Opened positions	41	58	-29.3%
Closed positions	43	26	+65.4%
Increased positions	106	88	+20.5%
Reduced positions	101	93	+8.6%

13F shares	Current	Prev Q	Change
Total value	2.83 tn	3.22 tn	-12.3%
Total shares	304.94 mm	306.70 mm	-0.6%
Total puts	514.70 k	833.10 k	-38.2%
Total calls	466.90 k	516.10 k	-9.5%
Total put/call ratio	1.1	1.6	-31.7%

Largest owners	Shares	Value	Change
Vanguard	29.26 mm	$275.62 bn	+1.6%
Wellington Management	28.46 mm	$268.11 bn	+18.8%
BlackRock	27.91 mm	$262.89 bn	+6.9%
Perceptive Advisors	24.25 mm	$228.40 bn	-13.6%
Avoro Capital Advisors	23.18 mm	$218.31 bn	0.0%
William Blair Investment Management	15.60 mm	$146.93 bn	+0.1%
STT State Street	10.36 mm	$97.60 bn	-5.6%
Citadel Advisors	8.24 mm	$77.62 bn	+127.0%
Palo Alto Investors	7.66 mm	$72.18 bn	-5.9%
JPM JPMorgan Chase & Co.	7.21 mm	$67.96 bn	-44.2%

Largest transactions	Shares	Bought/sold	Change
JPM JPMorgan Chase & Co.	7.21 mm	-5.71 mm	-44.2%
Citadel Advisors	8.24 mm	+4.61 mm	+127.0%
Wellington Management	28.46 mm	+4.50 mm	+18.8%
Perceptive Advisors	24.25 mm	-3.81 mm	-13.6%
Vestal Point Capital	3.35 mm	+3.35 mm	NEW
Norges Bank	3.08 mm	+3.08 mm	NEW
JHG Janus Henderson	3.40 mm	-2.94 mm	-46.4%
MS Morgan Stanley	2.12 mm	-2.09 mm	-49.7%
BlackRock	27.91 mm	+1.80 mm	+6.9%
Orbimed Advisors	2.29 mm	+1.72 mm	+300.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

FOLD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 Jun 25	Whitman Burke W	Common Stock	Grant	Acquire A	No	No	0	20,414	0.00	118,598
5 Jun 25	Whitman Burke W	Stock Options Common Stock	Grant	Acquire A	No	No	5.96	74,872	446.24 k	74,872
5 Jun 25	Wheeler Craig A	Common Stock	Grant	Acquire A	No	No	0	20,414	0.00	84,631
5 Jun 25	Wheeler Craig A	Stock Options Common Stock	Grant	Acquire A	No	No	5.96	74,872	446.24 k	74,872
5 Jun 25	Bleil Lynn Dorsey	Common Stock	Grant	Acquire A	No	No	0	20,414	0.00	113,941
5 Jun 25	Bleil Lynn Dorsey	Stock Options Common Stock	Grant	Acquire A	No	No	5.96	74,872	446.24 k	74,872
5 Jun 25	Roberts Eiry	Common Stock	Grant	Acquire A	No	No	0	20,414	0.00	76,275
5 Jun 25	Roberts Eiry	Stock Options Common Stock	Grant	Acquire A	No	No	5.96	74,872	446.24 k	74,872
5 Jun 25	Kelly Michael Aaron	Common Stock	Grant	Acquire A	No	No	0	20,414	0.00	72,468
5 Jun 25	Kelly Michael Aaron	Stock Options Common Stock	Grant	Acquire A	No	No	5.96	74,872	446.24 k	74,872